Design, Synthesis and Molecular Docking of Novel Quinazolinone Hydrazide Derivatives as EGFR Inhibitors
作者:Ze‐Yu Fang、Yi‐Heng Zhang、Chong‐Hao Chen、Qi Zheng、Peng‐Cheng Lv、Lei‐Qiang Ni、Juan Sun、Yuan‐Feng Wu
DOI:10.1002/cbdv.202200189
日期:2022.6
A series of novel quinazolinone hydrazide derivatives were designed and synthesized as EGFR inhibitors. The results indicated that most of the aimed compounds had potential anti-tumor cell proliferation and EGFR inhibitory activities. In the comprehensive analysis of all the tested compounds, the target compound 9c showed the best anti-tumor cell proliferation activity, (IC50 =1.31 μM for MCF-7, IC50
设计并合成了一系列新型喹唑啉酮酰肼衍生物作为EGFR抑制剂。结果表明,大多数目标化合物具有潜在的抗肿瘤细胞增殖和EGFR抑制活性。在所有受试化合物的综合分析中,目标化合物9c显示出最好的抗肿瘤细胞增殖活性,(MCF-7的IC50 =1.31 μM,HepG2的IC50 =1.89 μM,SGC的IC50 =2.10 μM),和EGFR 抑制活性的 IC50 =0.59 μM。对接结果表明,化合物9c可以理想地插入活性位点并与活性位点中的关键氨基酸残基(Val702、Lys721、Met769、Asp831)相互作用。